AzTrials
AzTrials

Coronary Artery DiseasePhase 3EPICNCT00355563

Study of the PAS-Port® Proximal Anastomosis System in Coronary Bypass Surgery

A Phase 3 study testing PAS-Port Automated Proximal Anastomosis System in people with Coronary Artery Disease, run by Cardica, Inc at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The study has been designed to comparatively evaluate the safety and effectiveness of the PAS-Port Proximal Anastomosis System and conventional suturing techniques for creation of the connection between graft veins and the aorta in patients undergoing coronary artery bypass graft surgery for treatment of coronary… Read more about this study

Who is it for?
Ages 50 to 85 years
Conditions the study is for
Coronary Artery Disease
What is being tested?
PAS-Port Automated Proximal Anastomosis System
Type of treatment
Medical device
How many people
220 participants
Where
1 siteUnited States
Study dates
Jun 2006to Apr 2008
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Able to give informed consent, able to understand the intent and clinical meaning of the study as well as its implications. Patient is legally competent.
  • Assessment that the patient is willing and able to have follow-up visits and examinations
  • Age greater than or equal to 50 years and less than 85 years
  • Ejection fraction of >30%
  • Can tolerate radiographic contrast media
  • Requires non-emergent coronary artery bypass with at least two vein bypass grafts intended
Show all 16Show fewer
  • Coronary artery targets intended for bypass index grafts must have >70% native stenosis
  • Life expectancy >1 year
  • Patient is hemodynamically stable
  • Open chest reassessment of the revascularization strategy confirms that two vein bypass grafts are still intended
  • Target vessel wall properties that are suitable for performing both a hand-sewn and a PAS-Port anastomosis
  • Target vessel is greater than 1.8 mm in diameter at sites where anastomoses are planned
  • Target vessel at sites where anastomoses will be placed are free from severe calcifications or severe atheromas
  • The length of the vein graft(s) is adequate for both of the planned index graft revascularization strategies
  • Vein outside diameter and double wall thickness are between 4 and 6 mm(inclusive) and less than or equal to 1.4 mm, respectively, at the graft site intended for the PAS-Port proximal anastomosis
  • The vein(s) is of suitable quality to be used as a bypass graft conduit

Who cannot join

  • Patient is participating in other clinical trials that would conflict with this protocol
  • Unable to meet study requirements (travel, general health)
  • Pregnancy
  • Previous cardiac surgery
  • Requiring preoperative use of an intraaortic balloon pump
  • Congestive heart failure / NYHA Class IV
Show all 15Show fewer
  • History of thromboembolic disease requiring ongoing anticoagulation therapy or the presence of a bleeding disorder
  • Acute or chronic dialysis
  • Creatinine of greater than 200 µmol/L (2.3 mg/dL) in the last 30 days
  • Documented acute or suspected systemic infection
  • Need for ongoing immunosuppressive therapy
  • Recent (less than 2 weeks) history of cerebrovascular accident
  • Aspirin allergy or other contraindications to aspirin use
  • INTRA-OPERATIVELY
  • -Any of the Intra-operative Inclusion Criteria not met

Trial locations and contacts

1 site in 1 country.

United States1 site
  • St. Michael's Medical Center

    Newark, New Jersey, 07102

Other trials in United States

About this study

Official title: Use of the PAS-Port Proximal Anastomosis System for Creation of Aorto-Venous Proximal Anastomoses in Coronary Bypass Surgery

The study has been designed to comparatively evaluate the safety and effectiveness of the PAS-Port Proximal Anastomosis System and conventional suturing techniques for creation of the connection between graft veins and the aorta in patients undergoing coronary artery bypass graft surgery for treatment of coronary artery disease. Patients in the study will have a coronary angiogram approximately 9 months following surgery to determine the patency of vein grafts created using either the automated PAS-Port or hand sewn methods. Safety will be evaluated by documenting the occurence of adverse clinical events and evealuating possible association with either method.

Being tested
PAS-Port Automated Proximal Anastomosis System
Medical subject headings
Coronary Artery Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PAS-Port Automated Proximal Anastomosis SystemDevice

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Effectiveness: Graft Patency at 9 months post-operatively

  2. Safety: Peri-and Post-operative MACE and SAE

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Jul 2006 (estimated)
  2. Study startJun 2006
  3. Primary completionDec 2007
  4. Study completionApr 2008

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Single group
Masking
Single blind
Enrolment
220 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00355563
Sponsor's protocol ID
IP2005-07
Acronym
EPIC
Status last verified
Jan 2009
First submitted
21 Jul 2006
Last updated
9 Jan 2009
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing PAS-Port Automated Proximal Anastomosis System in people with Coronary Artery Disease, run by Cardica, Inc at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 16 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Jan 2009. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Effectiveness: Graft Patency at 9 months post-operatively. The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jan 2009.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in